According to aspect of the present invention there is provided humus treatment process with active neurological substances, that is, the waste treatment process in the pharmaceutical industry. That uses raw materials from plants. The process involves treatment of fossil plants, Canabis sative, Mittragyna speciose, Datura metel and Magic mushrooms in order to allow residues in the plant to interact with the system. Nerves are depleted or less than the set value and allowing the production waste to be used in the processing of the fibers and agriculture industry.

A method of extracting active ingredients in mushrooms includes following steps: crushing a mushroom to obtain a crude mushroom crush; mixing the crude mushroom crush with deionized water to obtain a crude crush mixture; adding the crude crush mixture into a subcritical fluid extractor and extracting the crude crush mixture to obtain a crude mushroom extract; centrifuging the crude mushroom extract to harvest a first supernatant and a mushroom residue; mixing the mushroom residue with deionized water and a cellulase enzyme to obtain a reaction mixture; adding the reaction mixture into a high-pressure hydrolysis reactor and extracting the reaction mixture to obtain a hydrolysate; centrifuging the hydrolysate to obtain a second supernatant; and combining the first supernatant and the second supernatant, and then concentrating the combined first and second supernatants to obtain a mushroom extraction solution.

A method of extracting active ingredients in mushrooms includes following steps: crushing a mushroom to obtain a crude mushroom crush; mixing the crude mushroom crush with deionized water to obtain a crude crush mixture; adding the crude crush mixture into a subcritical fluid extractor and extracting the crude crush mixture to obtain a crude mushroom extract; centrifuging the crude mushroom extract to harvest a first supernatant and a mushroom residue; mixing the mushroom residue with deionized water and a cellulase enzyme to obtain a reaction mixture; adding the reaction mixture into a high-pressure hydrolysis reactor and extracting the reaction mixture to obtain a hydrolysate; centrifuging the hydrolysate to obtain a second supernatant; and combining the first supernatant and the second supernatant, and then concentrating the combined first and second supernatants to obtain a mushroom extraction solution.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

A composition for human consumption that combines various ingredients that boost stem cell activity. Illustrative ingredients may for example include high cacao content chocolate, medicinal mushroom extracts, substances containing or promoting DHEA, pine bark extract to convert arginine from cacao into nitric oxide to improve circulation. DHEA boosting substances may include truffle powder and/or pine pollen. An illustrative composition may have about 75% chocolate by weight, with cacao content of 73% or more, at least 10% truffle powder or pine pollen, at least 10% medicinal mushroom extracts, the remainder pine bark extract. The composition may be formulated into sublingual tablets of about 1 gram, and daily consumption may for example consist of 5 tablets for 5 grams total. Includes a method of supporting cardiovascular health, improving sexual performance and sexual health, and improving athletic performance by administering a therapeutic amount of the compound to a subject.